insights_auto
Why is DMN down 6,50%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
0,063 €
arrow_downward
-6,50%(-0,0044) 1D
11 նոյ, 20:16:11 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,07 €
High
0,07 €
Low
0,06 €
Mkt. cap
140,09 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,07 €
High
0,07 €
Low
0,06 €
Mkt. cap
140,09 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
Eurasia Business News
·
9 րոպե առաջ
Stock Market Today: Dow Jones, Nasdaq, S&P 500 Rally on November 11, 2026; Oil Rises, Gold Slips
marketscreener.com
·
43 րոպե առաջ
S&P 500's Earnings Growth to Slow in 2027, 2028, UBS Says
ChartMill
·
1 ժամ առաջ
S&P 500 Most Active Stocks on Nov. 11, 2026: Semiconductor and Tech Names Dominate
Traders Union
·
28 րոպե առաջ
S&P 500 dropped 19.35% and JOJO.Index was up 4.78% in the Q4 2018 backtest, Michael A. Gayed notes
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB